Introduction Several antihypertensive drugs are photosensitizing and may promote the development of malignant melanoma (MM), but evidence remains inconsistent. We sought to quantify the association between use of antihypertensive drugs and MM risk. Methods We systematically searched PubMed, Embase, and CENTRAL from inception to August 17, 2017 to identify observational studies that reported the MM risk associated with the use of antihypertensive drugs. A random-effects meta-analysis was used to estimate the odds ratio (OR) with 95% confidence interval (CI). Results Overall, we included eight observational studies (two cohort studies and six case-control studies). Compared with non-use, use of diuretics (OR 1.10; 95% CI 1.03-1.17) or b-adrenergic blocking agents (OR 1.19; 95% CI 1.04-1.37) was significantly associated with increased risk of MM. The use of angiotensin-converting enzyme inhibitors (OR 1.08; 95% CI 0.95-1.23), angiotensin II receptor blockers (OR 1.12; 95% CI 0.95-1.31), and calcium channel blockers (OR 1.12; 95% CI 0.72-1.74) was not significantly associated with increased risk of MM. Conclusions Current evidence from observational studies suggests that use of diuretics or b-adrenergic blocking agents may be associated with increased risk of MM. Further large well-conducted prospective studies are required to confirm our findings.
Introduction
Skin cancers are the most common human cancers, mainly caused by exposure to ultraviolet radiation (UVR) [1, 2] . However, their incidence is still increasing worldwide [3] , Electronic supplementary material The online version of this article (doi:10.1007/s40264-017-0599-x) contains supplementary material, which is available to authorized users. despite growing awareness of the harmful effects of sun exposure [4] . It is estimated that more than 8500 people in the USA are diagnosed with skin cancer every day [5] . Malignant melanoma (MM), the most serious skin cancer, accounts for less than 1% of skin cancer cases, but is responsible for most skin cancer deaths [6] . Several risk factors, such as UVR exposure, number of melanocytic nevi, familiar history, and genetic susceptibility, have been proposed to explain the incidence of MM [7] . Recently, some evidence indicated that drug use might be associated with increased risk of MM [8, 9] .
Antihypertensive drugs have been widely used to treat hypertension as well as other conditions including heart failure and arrhythmias [10] . It is estimated that about onethird of US adults suffer from hypertension [11] and are likely to take antihypertensive drugs. However, several antihypertensive drugs are described as photosensitizing and may act as co-carcinogens with UVR to promote MM development [12] . Among the five major classes of antihypertensive drugs-angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), b-adrenergic blocking agents (b-blockers), calcium channel blockers (CCBs), and diuretics-use of diuretics was found to be associated with an increased risk of MM in some studies [12, 13] . Similarly, a positive association was also detected between use of b-blockers and risk of MM [9, 14] . On the other hand, some studies did not find a positive association between either diuretics [9, 14] or b-blockers [15] and risk of MM. These inconsistent findings might result from the small sample size and variety in study durations and study populations in individual reports. Little is known about the risk of MM among individuals taking ACE inhibitors, ARBs, or CCBs. Moreover, there has been no previous systematic review and meta-analysis of the association between use of antihypertensive drugs and risk of MM. We therefore conduct this meta-analysis to determine whether any of the above five major classes of antihypertensive drugs was associated with MM risk.
Methods

Search Strategy and Study Selection
The electronic databases including PubMed, Embase, and Cochrane Central Register of Controlled Trials (CEN-TRAL) were systematically searched to identify observational studies (cohort and case-control studies) that evaluated the association between exposure to antihypertensive drugs and risk of MM. All of the databases were searched from inception to August 17, 2017, using combined terms (see the electronic supplementary material, Supplementary file 1) without any restriction. In addition, the reference lists of relevant reviews and meta-analyses were also checked to identify additional studies.
After excluding duplicate citations, two reviewers (HT and SF) independently reviewed titles and abstracts of the remaining studies to identify potential studies, which were further evaluated by retrieving their full texts. We included the studies that fulfilled the following inclusion criteria: (1) use of any antihypertensive drug as the exposure and no use of particular antihypertensive drug as the reference; (2) reported the outcome of MM; (3) reported the odds ratio (OR), relative risk (RR), hazard ratio (HR), or relevant estimates with 95% confidence intervals (CIs) or sufficient data to determine 95% CIs; and (4) observational studies, including cohort studies or case-control studies. We searched the above databases without any language restriction and included papers published in other languages. Of the potential studies, none was published in a language other than English. For multiple studies using the same populations, only the study with the latest or longest follow-up was included. If the article included multiple samples from different databases and reported their outcomes separately, we considered it as multiple studies. We excluded abstracts and unpublished studies because of limited information to assess quality. Furthermore, to prevent double-counting from duplications, two reviewers (HT and SF) doublechecked the data source and populations of the included studies.
Data Extraction and Quality Assessment
Two reviewers (HT and SF) independently extracted data and assessed the quality of each study. We collected the following information: study design, data source, number of participants, age (years), gender (%), selection criteria, exposure definition, reference definition, adjusted covariates, and the adjusted estimates. We also extracted data for further dose/time-response analyses. In addition, we assessed the quality of studies according to the NewcastleOttawa quality-assessment scale (NOS) [16] , which ranges from 0 to 9, with a higher score indicating better quality. In the case of any missing information, we contacted the original author for clarification. Any disagreements were resolved by consensus or referral to a third reviewer (JH).
Statistical Analysis
Due to similarities among the effect measures (HR, RR, and OR), when the number of events is low (\5%) [17] , ORs with 95% CIs were used to pool the outcome data in random-effects models. P values \0.05 were considered statistically significant. Heterogeneity was quantified using the I 2 statistic, with I 2 of \25, C25 and \75%, and C75%
indicating low, medium, and high heterogeneity, respectively [18] . Separate analyses were carried out for each class of antihypertensive drug. Furthermore, additional analyses were performed if there were sufficient data (at least six studies included [19] ). A subgroup analysis was performed by type of design, region of study, effect measure, and study quality to examine the source of heterogeneity. To present the development of evidence, we performed a cumulative meta-analysis based on date of publication to determine the year in which the association became significant. A sensitivity analysis was carried out to evaluate the effect of each study on the overall estimate by removing one study at a time. In addition, publication bias for risk of MM was assessed using Begg's and Egger's tests. All statistical analyses were performed with STATA (version 14; Stata Corp., College Station, TX, USA).
Results
Of 3360 citations retrieved from electronic databases, eight observational studies, i.e., two cohort studies [13, 20] and six case-control studies [9, 12, 14, 15, [21] [22] [23] , met the eligibility criteria and were included in our meta-analysis ( Fig. 1) . The main characteristics of the included studies are presented in Table 1 . Studies were published between 1996 and 2017. Six studies were carried out in Europe and two in the USA. Diuretics were used in six studies, ACE inhibitors in four studies, ARBs in three studies, b-blockers in three studies, and CCBs in two studies. OR was reported in five studies as an effect measure, incidence rate ratio (IRR) was reported in two studies, and RR was reported in one study. The included studies were of moderate or high quality. Four were assessed as high quality, with a NOS score of 8 out of 9, and the remaining studies were assessed as medium quality, with scores from 5 to 7 (Supplementary  Table 2 ).
Diuretics and Risk of MM
The pooled estimates of six studies showed that use of diuretics was associated with significantly increased risk of MM compared with non-use (OR 1.10, 95% CI 1.03-1.17), with no evidence of heterogeneity (I 2 = 0%) (Fig. 2) . Subgroup analyses by study design, region of study, quality of study, and effect measure were performed, and the results are presented in Supplementary Table 3 . A significantly increased risk of MM was identified in studies performed in European populations (OR 1.10; 95% CI 1.03-1.17), studies with high quality (OR 1.09; 95% CI 1.02-1.17), and studies reporting IRR as an effect measure (OR 1.12; 95% CI 1.03-1.21). Our cumulative meta-analysis indicated that an increased risk of MM had been evident since 2008 (OR 1.18; 95% CI 1.01-1.39) (Fig. 3) . Sensitivity analyses excluding one study at a time showed that no study significantly affected the overall estimates ( Supplementary Fig. 1 ). There was no evidence of publication bias based on Egger's test (P = 0.18) and Begg's test (P = 0.26).
b-Blockers and Risk of MM
Three studies reported data on the association between bblockers and risk of MM. When we pooled analysis of these studies, we found a significantly increased risk of MM (OR 1.19; 95% CI 1.04-1.37), with low evidence of heterogeneity (I 2 = 11.0%) (Fig. 2) . However, further analysis (e.g., subgroup analysis) was hampered because of the limited number of studies included.
Other Classes of Antihypertensive Drugs and Risk of MM
We identified positive associations between other classes of antihypertensive drugs and risk of MM, but they did not reach statistical significance (Fig. 2) . For ACE inhibitors, the OR for risk of MM was 1.08 (95% CI 0.95-1.23) in a pooled analysis of the data from four studies. There was low evidence of heterogeneity (I 2 = 3.4%). Three studies reported the risk of MM associated with ARBs, and their pooled analysis showed that OR for the risk of MM was 1.12 (95% CI 0.95-1.31), with no evidence of heterogeneity (I 2 = 0%). The OR between CCBs and risk of MM was 1.12 (95% CI 0.72-1.74), based on data from two studies, but significant heterogeneity was found (I 2 = 52.6%).
Dose/Time-Response Analyses
One study identified a trend of an increase in risk of MM among the users of indapamide (one type of diuretic) only, with an increase in IRR from 3.85 (95% CI 1.47-10.1) in a C1-year latency to 6.06 (95% CI 1.78-20.7) in a C5-year latency [12] . One study found that the long-term use of ARBs, ACE inhibitors, b-blockers, and CCBs was associated with increased risk of MM, but not short-term use [14] . However, the study by Koomen et al. did not detect either a dose-or time-response for ACE inhibitors or ARBs [21] .
Discussion
Our meta-analysis of eight observational studies involving a large overall number of participants and incident cases of MM provides evidence that use of diuretics or b-blockers is associated with a slight increase in the risk of MM. No significantly increased risk of MM was observed among patients using other classes of antihypertensive drugs (including ACE inhibitors, ARBs, and CCBs). For diuretics, our cumulative meta-analysis indicated that use was significantly associated with an increased risk of MM starting in 2008. In addition, a significantly increased risk of MM was identified in studies performed in Europe, high-quality studies, and studies reporting IRR as an effect measure.
There was no evidence of publication bias. However, our results should be interpreted with caution because of the limited number of studies included. The first-line treatment for hypertension usually involves diuretics [24] . It is estimated that in 2004, about one-third of patients in the USA visiting a physician to address hypertension were prescribed diuretics [25] . Among antihypertensive drugs, diuretics carry the highest risk of photosensitivity reactions [26] . However, despite the wide use of diuretics, little attention has been paid to the possible associated risk of MM. There is some evidence that a photosensitizing reaction followed by sun exposure may increase the likelihood of sunburn and photo-damage, which increases risk of MM [27] . It is well known that drug-induced photosensitivity may act as a co-carcinogen with UVR to promote MM development [12] . Some epidemiologic studies have found increased risk of MM associated with diuretics [12, 13, 20] . Consistent with those findings, our results from this meta-analysis showed that use of diuretics was significantly associated with increased risk of MM. Furthermore, our stratified analysis indicated a significantly increased risk of MM in European populations, but not in US populations, though this might be caused by the limited number of patients included in our meta-analysis. However, our meta-analysis did not differentiate further among diuretics, and not all diuretics had the same propensity to induce photosensitivity [28] . Jensen et al. observed a trend of an increase in risk of MM among the users of indapamide, but not other diuretics [12] .
It was interesting to find some evidence indicating a slightly increased risk of MM among patients taking bblockers. Some b-blockers (e.g., sotalol) were considered photosensitizing [29] , and therefore might increase MM development by acting as co-carcinogens with UVR. In a population-based, matched case-control study from southern Sweden, Westerdahl et al. found a 70% increased risk in patients who used b-blockers as compared with non- Fig. 1 Flow chart of the identification of eligible studies. MM malignant melanoma [9] . Recently, one population-based, case-control study performed in northern Denmark found a weak association between use of b-blockers and risk of MM [14] . However, because of the limited number of studies we included, whether the weak association may be caused by chance influenced by confounders or represents a true association needs to be further investigated. We found some evidence suggesting an increased risk of MM associated with other classes of antihypertensive drugs (ACE inhibitors, ARBs, and CCBs), but the associations were not statistically significant, which might be caused by our limited sample. Additionally, one study found that long-term use of ACE inhibitors, ARBs, b-blockers, or CCBs was associated with increased risk of MM [14] . However, little is known about the possible mechanisms underlying any carcinogenic risk associated with other classes of antihypertensive drugs. An explanation might be that some antihypertensive drugs have been reported to elicit photosensitivity and phototoxicity, which might mediate an increased risk of MM associated with UVR [14] . However, we did not find a consistently increased risk of MM across these classes of antihypertensive drugs, which might be related to the fact that photosensitizing effects differed based on drug classes or pathways involved. In contrast, some evidence from both experimental and epidemiologic studies indicated some chemopreventive effects of ACE inhibitors and ARBs against cancer, with possible mechanisms of action including inhibition of matrix metalloprotease activity, reduced expression of vascular endothelial growth factor, and Table 1 . ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, b-blockers b-adrenergic blocking agents, CCBs calcium channel blockers, CI confidence interval, MM malignant melanoma interference with the renin-angiotensin system [30] . In our meta-analysis, the use of ACE inhibitors or ARBs did not seem to protect against the development of MM, which was consistent with published observational studies [13] [14] [15] 21] . Therefore, further large well-conducted studies involving dose-response analyses are required to clarify the MM risk among these classes of antihypertensive drugs.
Our study has two strengths. First, we systematically searched electronic databases to include all relevant studies. It is important to note that this is the first meta-analysis to address the association between antihypertensive drugs and risk of MM. Second, to confirm the robustness of our findings, pre-specified subgroup analysis and sensitivity analysis were performed. We also acknowledge that our meta-analysis has several limitations. First, common risk factors for MM, such as sun exposure, ethnicity, and smoking status, could not be adjusted for in the subgroup analysis, because of inconsistent control for potential confounders from included studies. Second, one potential confounder, health-seeking behavior, may lead to detection bias. Individuals under hypertension management may be more likely to seek medical advice and be subject to increased surveillance, which may increase probability of disease diagnosis. However, we did not detect an increased risk of MM across all classes of antihypertensive drugs, which suggested that the increased risk might not be entirely due to increased scrutiny. Third, of the studies we analyzed, only one (Koomen et al.) provided the information on cumulative doses or cumulative durations [21] , which prevented us from performing a further dose-response analysis or time-dependency analysis. Finally, due to the limited number of studies included, our results for ACE inhibitors, ARBs, b-blockers, and CCBs were inconsistent and therefore hinder any firm conclusions.
Conclusions
Our meta-analysis indicates that use of diuretics or bblockers may be associated with increased risk of MM. There was little evidence supporting increased risk of MM with other classes of antihypertensive drugs (ACE inhibitors, ARBs, and CCBs). Further large well-conducted prospective studies with dose-or time-response analyses and clear adjustment for confounders are required to confirm our findings.
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